Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Company Profiles

Set Alert for Emerging Company Profiles

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

Emergex Goes To Battle Against ‘The Nasties’

Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.

Emerging Company Profile Vaccines

PureTech Hopes For A Second Lightning Strike

Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?

Emerging Company Profile Commercial

Kiromic Looks To Prove Itself In Lung Cancer

Emerging Company Profile: Encouraging, but early, data on a gamma-delta T-cell therapy could position Kiromic BioPharma for deal-making.

Emerging Company Profile Business Strategies

Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies

Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma. 

Sweden Emerging Company Profile

Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease

Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.

China Emerging Company Profile

Freya Biosciences Has $38m And A Plan To Change Women’s Lives

Emerging Company Profile: Armed with a new tranche of funding, the Danish group is aiming to improve the lot of infertile couples by altering the microbiome of patients with dysbiosis.

Emerging Company Profile Companies

Kura Continues Araxes Legacy With New Menin And FTI Focuses In Cancer

Emerging Company Profile: The US biotech is advancing a pipeline of precision medicines targeting menin and farnesyltransferase for liquid and solid tumors, respectively, building on the work of two pioneering companies in the KRAS space.

Emerging Company Profile ImmunoOncology

SpyGlass To Boost Ophthalmic Drug Adherence With Intraocular Delivery Platform

Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.

Emerging Company Profile Financing

Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs

Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.

Financing Business Strategies

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

Emerging Company Profile ImmunoOncology

Kinaset Advances Inhaled Pan-JAK Inhibitor For Broad Use In Severe Asthma

Emerging Company Profile: The US biotech acquired its sole asset from CDMO Vectura in 2020 and is now gearing up for a Phase II proof-of-concept trial in severe asthma to help address the unmet need in non-eosinophilic patients.

Emerging Company Profile Companies

NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach

Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.

Emerging Company Profile Cancer

EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2

Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.

Emerging Company Profile ImmunoOncology

Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy

Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.

Emerging Company Profile Rare Diseases
See All